We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Allakos Inc
7 own
13 watching
Current Price
$1.01
$-0.01
(-0.98%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
419.82M
52-Week High
5.64000
52-Week Low
0.97990
Average Volume
0.38M
Dividend Yield
--
P/E Ratio
--
Market Capitalization419.82M52-Week High5.6400052-Week Low0.97990Average Volume0.38MDividend Yield--P/E Ratio--What does the Allakos Inc do?
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company s lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Read More
How much money does Allakos Inc make?
News & Events about Allakos Inc.
Zolmax
1 year ago
Cantor Fitzgerald reiterated their overweight rating on shares of Allakos (NASDAQ:ALLK Get Rating) in a report published on Tuesday , Benzinga reports. Cantor Fitzgerald currently has a $7.00 target price on the stock. ALLK has been the subject of a number of other reports. Piper Jaffray Companies ...
Ticker Report
1 year ago
Piper Sandler assumed coverage on shares of Allakos (NASDAQ:ALLK Get Rating) in a report released on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $22.00 target price on the stock. A number of other equities research analysts have also recently commented on...
Zolmax
1 year ago
Research analysts at Piper Sandler initiated coverage on shares of Allakos (NASDAQ:ALLK Get Rating) in a report released on Tuesday, MarketBeat reports. The brokerage set an overweight rating and a $22.00 price target on the stock. Piper Sandlers target price indicates a potential upside of 260.07% ...
Zolmax
1 year ago
Allakos Inc. (NASDAQ:ALLK Get Rating) Equities researchers at Jefferies Financial Group lifted their FY2022 EPS estimates for Allakos in a note issued to investors on Monday, November 7th. Jefferies Financial Group analyst M. Raycroft now expects that the company will post earnings per share of ($5....
Globe Newswire
1 year ago
Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells AK007 potently blocks all known ligand interaction with Siglec-10, including the dont eat me signal CD24 Monotherapy treatment with a Siglec-10 antagonist antibody polarized tumor-...
Frequently Asked Questions
Frequently Asked Questions
What is Allakos Inc share price today?
Can Indians buy Allakos Inc shares?
How can I buy Allakos Inc shares from India?
Can Fractional shares of Allakos Inc be purchased?
What are the documents required to start investing in Allakos Inc stocks?
What is today’s traded volume of Allakos Inc?
What is today’s market capitalisation of Allakos Inc?
What is the 52-Week High and Low Range of Allakos Inc?
What percentage is Allakos Inc down from its 52-Week High?
What percentage is Allakos Inc up from its 52-Week Low?
Current Price
$1.01
$-0.01
(-0.98%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.